Trial of Ixazomib for Kaposi Sarcoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

November 7, 2023

Primary Completion Date

March 15, 2029

Study Completion Date

March 15, 2029

Conditions
Kaposi SarcomaSkin
Interventions
DRUG

Ixazomib Citrate

Given PO

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (10)

10029

RECRUITING

Mount Sinai Hospital, New York

19106

RECRUITING

Abramson Cancer Center at Pennsylvania Hospital, Philadelphia

21287

RECRUITING

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

33136

RECRUITING

University of Miami Miller School of Medicine, Miami

60612

RECRUITING

University of Illinois Cancer Center, Chicago

63110

RECRUITING

Washington University, St Louis

77004

RECRUITING

Thomas Street Clinic, Houston

92093

RECRUITING

UC San Diego, San Diego

94110

RECRUITING

Zuckerberg San Francisco General Hospital, San Francisco

98101

RECRUITING

Virginia Mason Medical Center, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

AIDS Malignancy Consortium

NETWORK